...
首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Overall survival analysis of adjuvant radiation versus observation in stage i testicular seminoma: A surveillance, epidemiology, and end results (SEER) analysis
【24h】

Overall survival analysis of adjuvant radiation versus observation in stage i testicular seminoma: A surveillance, epidemiology, and end results (SEER) analysis

机译:辅助放射线总体生存分析与第i期睾丸精原细胞瘤的观察:监测,流行病学和最终结果(SEER)分析

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE:: The standard adjuvant treatment for men with stage I testicular seminoma remains controversial within the literature. We analyzed survival rates in men with stage I seminoma who underwent adjuvant radiation therapy (RT) or observation (OB) after orchiectomy. METHODS:: Data were obtained from the Surveillance, Epidemiology, and End Results program of the National Cancer Institute from 1973 to 2003. The primary end points were overall survival (OS) and cause-specific survival (CSS). Multivariate Cox regression models were used to study the significance of clinical variables: age at diagnosis, laterality of primary disease, race, and radiation group. RESULTS:: Of 6764 patients eligible for analysis, 5265 were treated with RT and 1499 with OB. After a median follow-up of 7.6 years, the 5-, 10-, and 20-year OS rates for the RT versus OB were 97.9 versus 95.0, 94.8 versus 92.2, and 83.5 versus 84.1 (P=0.0047), respectively. The CSS rates for the same time periods were 99.6 versus 98.7, 99.4 versus 98.7, and 99.2 versus 98.7 (P=0.0015), respectively. Adjuvant RT was associated with improved CSS on multivariate analysis with hazard ratio of 0.37 (confidence interval, 0.20-0.70; P=0.0023). CONCLUSIONS:: Within this large US population analysis, adjuvant RT was associated with improved OS and CSS compared with OB for men with stage I testicular seminoma. Further studies are needed to determine whether modern RT techniques and field-size reductions may lead to greater improvements in the therapeutic ratio, in light of the trend toward chemotherapy as primary treatment.
机译:目的:男性I期睾丸精原细胞瘤的标准辅助治疗在文献中仍存在争议。我们分析了睾丸切除术后接受辅助放疗(RT)或观察(OB)的I期精原细胞瘤患者的生存率。方法:数据是从1973年至2003年美国国家癌症研究所的监测,流行病学和最终结果计划获得的。主要终点是总体生存期(OS)和特定原因生存期(CSS)。使用多变量Cox回归模型研究临床变量的重要性:诊断年龄,原发疾病的偏侧性,种族和放射线组。结果:在6764名符合分析条件的患者中,有5265例接受了RT治疗,1499例接受了OB治疗。在中位随访7.6年后,RT与OB的5年,10年和20年OS率分别为97.9对95.0、94.8对92.2和83.5对84.1(P = 0.0047)。同一时期的CSS比率分别为99.6对98.7、99.4对98.7和99.2对98.7(P = 0.0015)。在多变量分析中,佐剂放疗与CSS改善相关,危险比为0.37(置信区间为0.20-0.70; P = 0.0023)。结论:在美国的这一大规模人群分析中,与Ib期男性睾丸精原细胞瘤相比,佐剂RT与OS和CSS改善相关。考虑到趋向于将化学疗法作为主要治疗方法的趋势,需要进一步研究以确定现代RT技术和缩小视野大小是否可以导致治疗率的更大提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号